Amerikanische Gesellschaft für Hirudotherapie

Lethal Sepsis in the Course of Medicinal Leech Therapy

Case report published in Antibiotics (2022)

Zuletzt aktualisiert: June 18, 2026Geprüft von: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Case reportSicherheit & InfektionskontrolleSproll C, Lommen J, Balasiu A et al. · Antibiotics, 2022

Abstract

A patient with oral squamous cell carcinoma (OSCC) underwent complex surgical tumor therapy, including the reconstruction of soft tissues using a radial forearm flap. Due to venous congestion that could only partly be resolved by revision surgery, leech therapy was started on the second postoperative day. The patient developed pneumonia and sepsis and died as a result of septic shock, despite having received targeted broad-spectrum antibiotic therapy since day 5. Aeromonas spp. were cultured from both the patient's specimens and unused leeches. Biochemical identification and matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF MS) yielded inconsistent identification results. Finally, microbiological identification of Aeromonas spp. was performed via 16S rDNA sequencing and use of the basic local alignment search tool (BLAST), and strains from both the patient and the leeches were identified as Aeromonas veronii. Aeromonas spp. strains derived from the patient and leeches and independent laboratory strains were submitted to randomly amplified polymorphic DNA (RAPD) subtyping. RAPD of A. veronii strains from both sources revealed an identical pattern, strongly suggesting the transmission of A. veronii from the leeches to the patient. Physicians should be aware of the potential for severe lethal infections as a fatal side-effect of leech therapy in critically ill patients, which should be addressed using antibiotic prophylaxis.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeCase ReportsJournal Article

Zusammenfassung

Patient with oral squamous cell carcinoma receiving leech therapy after radial forearm flap died of Aeromonas septic shock; RAPD subtyping confirmed identical strains from patient and leeches, definitively proving leech-to-patient transmission.

Warum dies für die Hirudotherapie relevant ist

This case report describes a patient with oral squamous cell carcinoma who developed fatal septic shock after leech therapy for venous congestion of a radial forearm flap. Aeromonas veronii was cultured from both the patient and unused leeches, and RAPD subtyping revealed identical patterns, strongly suggesting leech-to-patient transmission. The patient had received broad-spectrum antibiotics from day five but succumbed to pneumonia and sepsis. This case is directly relevant to hirudotherapy safety, demonstrating that Aeromonas transmission from medicinal leeches can cause lethal infection in critically ill patients and underscoring the importance of antibiotic prophylaxis. However, this represents a single fatal case in a medically complex oncology patient, and MALDI-TOF MS yielded inconsistent species identification, requiring 16S rDNA sequencing for definitive identification.

Zitation

Lethal Sepsis in the Course of Medicinal Leech Therapy.

Sproll C, Lommen J, Balasiu A et al. · Antibiotics, 2022

Verwandter klinischer Kontext

Erfahren Sie, wie diese Forschung mit der klinischen Praxis verknüpft ist

Zur ASH-Bibliothek hinzugefügt: May 26, 2026 · Letzte Aktualisierung der Website: June 18, 2026

Diese Website stellt Bildungsinformationen bereit und ist weder eine medizinische Beratung noch eine Diagnose oder Behandlungsempfehlung. Die medizinische Blutegeltherapie ist mit klinisch relevanten Risiken verbunden und sollte ausschließlich von qualifizierten Klinikerinnen und Klinikern unter institutionell genehmigten Protokollen durchgeführt werden. Die FDA-510(k)-Zulassung für medizinische Blutegel ist auf bestimmte Indikationen beschränkt; experimentelle und Off-Label-Diskussionen werden entsprechend gekennzeichnet. Für patientenspezifische Beratung wenden Sie sich an eine qualifizierte Gesundheitsfachkraft.